Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohua Yu

Showing results (231-240 of 237) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 237 results.
Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.
Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
JAMA|January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical TrialShun Lu, Wei Zhang, Lin Wu, et al.
JAMA Surgery|July 15, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical TrialWentao Fang, Yiyang Wang, Wenxiang Wang, et al.
Nature Medicine|March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 24

Showing results (231-240 of 237) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 237 results.
Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.
Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
JAMA|January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical TrialShun Lu, Wei Zhang, Lin Wu, et al.
JAMA Surgery|July 15, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical TrialWentao Fang, Yiyang Wang, Wenxiang Wang, et al.
Nature Medicine|March 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Nature Medicine|January 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Yanqiao Zhang, Ziyu Li, et al.
Pageof 24